课题基金 / 基金详情

Suppression of MHC expression on corneal cells to prevent immune rejection after allogeneic transplantation: Experimental investigation in a mouse model

Suppression of MHC expression on corneal cells to prevent immune rejection after allogeneic transplantation: Experimental investigation in a mouse model
抑制角膜细胞上的 MHC 表达以防止同种异体移植后的免疫排斥:小鼠模型的实验研究
批准号:
243145653
负责人:
Professorin Dr. Katrin Engelmann
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2013
资助国家:
德国
项目状态:
已结题
起止时间:
2012-12-31 至 2018-12-31

项目摘要

项目成果

Professorin Dr. Katrin Engelmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The high variability of the major histocompatibility complex (MHC), in humans histocompatibility leukocyte antigen (HLA) complex, and of the minor histocompatibility antigens (mHA) significantly contributes to elicit an immune response after allogeneic cornea transplantation, and may lead to the development of acute or chronic rejection. In addition, an often inevitable second cornea transplantation is always associated with an increased risk of graft rejection. This project aims to permanently reduce HLA class I and class II expression on cornea transplants to decrease the risk of graft rejection after keratoplasty. This method represents a new therapeutic concept and may contribute to prevent graft rejection. RNA-interference technology will be used to induce the downregulation of MHC expression. This method not only silences the expression of MHC molecules on the cell surface but also contributes to abrogate the presentation of minor histocompatibility antigens derived from other polymorphic molecules. Previously, we demonstrated that silencing HLA expression in a permanent manner can efficiently abrogate a deleterious immune response against allogeneic cells and significantly prolongs the survival of cells after allogeneic transplantation. In addition we have shown the feasibility of silencing HLA class I expression in human cornea endothelium in its original 3D-structure. In the proposed study, the transplantation and monitoring of rejection of manipulated and non-manipulated corneas will be performed in a mouse keratoplasty model for graft rejection (BALB/c and C3H). A lentiviral system will be used for the delivery of short hairpin RNA (shRNA) targeting mouse beta2-microglobulin or targeting the alpha chain of H2-E (H2-Ea). The presence of antigen presenting cells (APCs) and rejection markers will be assessed at defined time points. In addition, morphological changes after silencing MHC expression and cornea transplantation will be analysed by microscopy. Also, apoptosis and necrosis in the corneas will be evaluated. This study presents a new strategy to overcome the limitations and drawbacks caused by HLA mismatches in keratoplasty.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
RNA Interference as a Tool to Reduce the Risk of Rejection in Cell-Based Therapies
RNA 干扰作为降低细胞疗法排斥风险的工具
DOI: 10.5772/61829
发表时间: 2016
期刊:
影响因子: --
作者: [Figueiredo C, Blasczyk R]
通讯作者: Blasczyk R
48. Jahreskongress der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI), 15.-18. September 2015, Basel: Abstracts
德国输血医学和免疫血液学学会 (DGTI) 第 48 届年会,2015 年 9 月 15-18 日,巴塞尔:摘要
DOI: --
发表时间: 2015
期刊: Transfusion Medicine and Hemotherapy
影响因子: 2.2
作者: [Börger AK, Mueller C, Wittig D, Blasczyk R, Engelmann K, Figueiredo C]
通讯作者: Figueiredo C
Tissue engineering of the human corneal endothelium: From primary cell culture to transplantation of highly functional cell sheets
Entwicklung von schaltbaren Polymersubstraten zur Gewinnung transplantierbarer zellulärer Sheets sowie technischer Hilfsmittel zum Transfer am Beispiel des humanen cornealen Endothels
In vitro and clinical comparison of corneal grafts cultured in serum free medium or standard serum supplemented medium in patients with degeneration of the corneal endothelium
  • 批准号:
    34896408
  • 项目类别:
    Clinical Trials
  • 资助金额:
    $0.0万
  • 财政年份:
    2007
  • 负责人:
    Professorin Dr. Katrin Engelmann
  • 依托单位:
国内基金
海外基金
MHC-I/CD14介导CD8+T细胞免疫抑制促进去势抵抗前列腺癌免疫逃逸的研究
  • 批准号:
    2026JJ50277
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    钟上伟
  • 依托单位:
去泛素化酶USP9X调控抗原呈递分子MHC-I的机制研究
  • 批准号:
    JCZRQNB202600282
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
西黄丸通过m6A修饰介导YTHDF2/FAM13A/STUB1轴调控PCSK9-MHC-I信号逆转乳腺癌免疫逃逸的机制研究
BCAT2调控氨基酸代谢重编程抑制MHC-I类分子组蛋白乙酰化修饰协助免疫逃逸的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    蔡智勇
  • 依托单位: